Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.
Department of Medicine, National Taiwan University, Taipei City 100, Taiwan.
Medicina (Kaunas). 2024 Aug 14;60(8):1311. doi: 10.3390/medicina60081311.
: Our study compared the visual and anatomical outcomes of polypoidal choroidal vasculopathy (PCV) patients receiving intravitreal aflibercept (IVA) with or without photodynamic therapy (PDT) over 12 months. : This retrospective study was performed for 60 eyes from 60 patients with treatment-naïve PCV. Thirty eyes were treated using IVA monotherapy (IVA group), and thirty eyes were treated using a combination of IVA with PDT (IVA/PDT group). The baseline characteristics, treatment outcomes, and retreatment rates were compared between the two groups over a one-year follow-up period. : The best-corrected visual acuity (BCVA) was found to have improved significantly in the IVA/PDT group at every 3-month visit. However, no significant BCVA improvement was observed in the IVA group. A significantly lower retreatment rate and higher dry macula rate were found in the IVA/PDT group than that in the IVA group. In the entire population of the study, a better baseline vision and younger age were associated with better final visual outcomes. Retreatment was associated with poor baseline BCVA and IVA monotherapy. : The combination of IVA and PDT may offer superior visual improvement and a higher dry macula rate compared to IVA monotherapy in the treatment of PCV patients while requiring fewer retreatments over 12 months.
: 本研究比较了 60 例未经治疗的 PCV 患者在 12 个月内接受玻璃体内阿柏西普（IVA）联合或不联合光动力疗法（PDT）的视觉和解剖学结果。 : 这是一项回顾性研究，共纳入 60 例患者的 60 只眼。其中 30 只眼接受 IVA 单药治疗（IVA 组），30 只眼接受 IVA 联合 PDT 治疗（IVA/PDT 组）。比较两组在 1 年随访期间的基线特征、治疗效果和再治疗率。 : 在 IVA/PDT 组，在每次 3 个月的随访中最佳矫正视力（BCVA）均显著提高。然而，IVA 组的 BCVA 无显著改善。与 IVA 组相比，IVA/PDT 组的再治疗率较低，干性黄斑发生率较高。在研究的所有患者中，更好的基线视力和更年轻的年龄与最终更好的视觉结局相关。再治疗与较差的基线 BCVA 和 IVA 单药治疗相关。 : 在治疗 PCV 患者时，与 IVA 单药治疗相比，IVA 联合 PDT 可能提供更好的视力改善和更高的干性黄斑发生率，同时在 12 个月内需要更少的再治疗。
